Share this Page:
The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019.
Dr Brian Rini from the Cleveland Clinic Taussig Cancer Institute presented the results from a phase 3 clinical trial (TIVO-3) to compare the efficacy and safety of tivozanib to sorafenib in patients with metastatic renal cell carcinoma (RCC) who had failed treatment with 2-3 prior systemic therapies. The trial was used to confirm the progression-free survival data from the phase 3 TIVO-1 trial.
The results of the trial proved tivozanib to be superior to sorafenib in terms of median progression-free survival (5.6 months versus 3.9 months), objective response rate (18% versus 8%) and tolerability.